CXCR4-directed theranostics in oncology and inflammation

被引：111
作者：
Kircher, Malte [1 ]
Herhaus, Peter [2 ]
Schottelius, Margret [3 ]
Buck, Andreas K. [1 ]
Werner, Rudolf A. [1 ,4 ]
Wester, Hans-Juergen [3 ]
Keller, Ulrich [2 ]
Lapa, Constantin [1 ]
机构：
[1] Univ Hosp Wurzburg, Dept Nucl Med, Oberdurrbacher Str 6, D-97080 Wurzburg, Germany
[2] Tech Univ Munich, Internal Med Hematol & Med Oncol 3, Munich, Germany
[3] Tech Univ Munich, Pharmaceut Radiochem, Munich, Germany
[4] Johns Hopkins Univ, Sch Med, Div Nucl Med & Mol Imaging, Baltimore, MD USA
来源：
ANNALS OF NUCLEAR MEDICINE | 2018年 / 32卷 / 08期
关键词：
Chemokine; Cancer; Theranostics; Pentixafor; Pentixather; CHEMOKINE RECEPTOR CXCR4; GA-68; PENTIXAFOR; IN-VIVO; DIFFERENTIAL EXPRESSION; PRECLINICAL EVALUATION; INTERNATIONAL UNION; ANTI-CXCR4; ANTIBODY; RADIATION-DOSIMETRY; HEMATOPOIETIC STEM; CXCR4-TARGETED PET;
D O I：
10.1007/s12149-018-1290-8
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
Given its prominent role in inflammation and cancer biology, the C-X-C motif chemokine receptor 4 (CXCR4) has gained a lot of attention in the recent years. This review gives a short overview of the physiology and pathology of chemokines and chemokine receptors and then focuses on the current experience of targeting CXCR4, using radiolabeled receptor ligands suitable for positron emission tomography (PET) imaging, in both hematologic and solid malignancy as well as in inflammatory conditions. Additionally, CXCR4-directed endoradiotherapy (ERT) as a new treatment option is discussed.
引用
收藏
页码：503 / 511
页数：9
相关论文
共 122 条
[1]   Report of an international workshop to standardize baseline evaluation and response criteria for primary CNS lymphoma [J].
Abrey, LE ;
Batchelor, TT ;
Ferreri, AJM ;
Gospodarowicz, M ;
Pulczynski, EJ ;
Zucca, E ;
Smith, JR ;
Korfel, A ;
Soussain, C ;
DeAngelis, LM ;
Neuwelt, EA ;
O'Neill, BP ;
Thiel, E ;
Shenkier, T ;
Graus, F ;
van den Bent, M ;
Seymour, JF ;
Poortmans, P ;
Armitage, JO ;
Cavalli, F .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (22) :5034-5043
[2]  
[Anonymous], EUR J NUCL MED MOL I
[3]  
[Anonymous], 2018, J NUCL MED
[4]  
[Anonymous], INVEST RADIOL
[5]  
[Anonymous], JACC CARDIOVASC IMAG
[6]  
[Anonymous], J THORAC CARDIOVASC
[7]  
[Anonymous], 2016, ONCOTARGET
[8]  
[Anonymous], 2018, BR J HAEMATOL
[9]  
Arya Manit, 2004, J Exp Ther Oncol, V4, P291
[10]   A fully human CXCR4 antibody demonstrates diagnostic utility and therapeutic efficacy in solid tumor xenografts [J].
Azad, Babak Behnam ;
Chatterjee, Samit ;
Lesniak, Wojciech G. ;
Lisok, Ala ;
Pullambhatla, Mrudula ;
Bhujwalla, Zaver M. ;
Pomper, Martin G. ;
Nimmagadda, Sridhar .
ONCOTARGET, 2016, 7 (11) :12344-12358
12345678910